产品
编 号：F461386
分子式：C22H25Cl2N3O
分子量：418.36
分子式：C22H25Cl2N3O
分子量：418.36
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
100mg
296
In-stock
200mg
448
In-stock
结构图
CAS No: 79307-93-0
产品详情
生物活性：
Azelastine hydrochloridem, an antihistamine, is a potent and selective histamine 1 (H1) antagonist. Azelastine hydrochloride can be used for the research of allergic rhinitis, asthma, diabetic hyperlipidemic and SARS-CoV-2.
体内研究：
Azelastine hydrochloride (4 mg/kg; p.o.; daily; for 8 weeks) significantly reduces blood glucose, HbA1c and serum alkaline phosphatase (ALP), osteocalcin and downregulates apolipoprotein B in diabetic hyperlipidemic rats model.Azelastine hydrochloride (4 mg/kg; p.o.; daily; for 8 weeks) improves the lipid profile (LDL-c decrease and HDL-c increase) in diabetic hyperlipidemic rats model.Azelastine hydrochloride (4 mg/kg; p.o.; daily; for 8 weeks) attenuates calcium deposition and aortic calcification in diabetic hyperlipidemic rats model.Animal Model:Male albino Wistar rats (150-170 g), diabetic hyperlipidemic rats model
Dosage:4 mg/kg
Administration:Oral administration, daily, for 8 weeks
Result:Ameliorated aortic calcification and increased apolipoprotein A expression along with a decline in apolipoprotein B.
体外研究：
Azelastine hydrochloride can significantly inhibit HNEpC proliferation, and therefore, be helpful in against airway remodeling.
Azelastine hydrochloridem, an antihistamine, is a potent and selective histamine 1 (H1) antagonist. Azelastine hydrochloride can be used for the research of allergic rhinitis, asthma, diabetic hyperlipidemic and SARS-CoV-2.
体内研究：
Azelastine hydrochloride (4 mg/kg; p.o.; daily; for 8 weeks) significantly reduces blood glucose, HbA1c and serum alkaline phosphatase (ALP), osteocalcin and downregulates apolipoprotein B in diabetic hyperlipidemic rats model.Azelastine hydrochloride (4 mg/kg; p.o.; daily; for 8 weeks) improves the lipid profile (LDL-c decrease and HDL-c increase) in diabetic hyperlipidemic rats model.Azelastine hydrochloride (4 mg/kg; p.o.; daily; for 8 weeks) attenuates calcium deposition and aortic calcification in diabetic hyperlipidemic rats model.Animal Model:Male albino Wistar rats (150-170 g), diabetic hyperlipidemic rats model
Dosage:4 mg/kg
Administration:Oral administration, daily, for 8 weeks
Result:Ameliorated aortic calcification and increased apolipoprotein A expression along with a decline in apolipoprotein B.
体外研究：
Azelastine hydrochloride can significantly inhibit HNEpC proliferation, and therefore, be helpful in against airway remodeling.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备